Wells Fargo & Company Uro Gen Pharma Ltd. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Wells Fargo & Company holds 221,540 shares of URGN stock, worth $2.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
221,540
Previous 215,739
2.69%
Holding current value
$2.11 Million
Previous $2.74 Million
13.87%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding URGN
# of Institutions
137Shares Held
36.2MCall Options Held
57.7KPut Options Held
9.8K-
Rtw Investments, LP New York, NY3.83MShares$36.5 Million0.67% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.93MShares$27.8 Million0.06% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$21.9 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$20.9 Million0.0% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A61.75MShares$16.6 Million0.03% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $216M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...